Pricing Log in Create free account

Corbus Pharmaceuticals Holdings, Inc. (CRBP) vs Xilio Therapeutics, Inc. (XLO)

Corbus Pharmaceuticals Holdings, Inc. and Xilio Therapeutics, Inc. are both Biotechnology companies. Corbus Pharmaceuticals Holdings, Inc. and Xilio Therapeutics, Inc. are of similar size ($55.9M and $55.3M). Xilio Therapeutics, Inc. grew revenue faster over the last twelve months: 327.3% against −73.7%. Corbus Pharmaceuticals Holdings, Inc. has the higher net margin (0.00% vs −34.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Xilio Therapeutics, Inc. leads on 8 and Corbus Pharmaceuticals Holdings, Inc. on 7.

Valuation

Metric CRBP XLO Biotechnology median
P/E n/m n/m 10.60
P/S 38.44 2.61 9.40
P/B 0.58 2.32 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.34 n/m 0.66
EV/Sales (23.77) 0.51 9.02
Earnings yield (202.95%) (17.27%) (32.88%)
Free cash flow yield (146.45%) (36.59%) (23.13%)

Profitability

Metric CRBP XLO Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% (48.94%) 0.00%
Net margin 0.00% (34.06%) 0.00%
Free cash flow margin 0.00% (95.59%) 0.00%
Return on equity (95.58%) (55.03%) (51.96%)
Return on assets (80.85%) (15.16%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CRBP XLO Biotechnology median
Revenue growth (TTM) (73.69%) 327.25% 6.76%
EPS growth (last fiscal year) (60.33%) 72.55% 29.88%
Revenue growth, 5-year CAGR (14.34%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRBP XLO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.71 4.25 4.97
Net debt to EBITDA 1.90 3.40 1.01

Dividend

Metric CRBP XLO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CRBP XLO Biotechnology median
Market cap 55.32m 55.93m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack